380 related articles for article (PubMed ID: 36466552)
1. Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.
Meng W; Jiang Z; Zhang X; Cai B; Ma L; Guan Y
Comput Math Methods Med; 2022; 2022():3119721. PubMed ID: 36466552
[TBL] [Abstract][Full Text] [Related]
2. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
3. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5.
Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW
Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205
[TBL] [Abstract][Full Text] [Related]
4. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
PeerJ; 2022; 10():e14432. PubMed ID: 36518297
[TBL] [Abstract][Full Text] [Related]
5. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer Analysis of the Prognostic and Immunological Role of SMG5: A Biomarker for Cancers.
Yang L; Wei J; Ma X; Cheng R; Zhang H; Jin T
Oncology; 2024; 102(2):168-182. PubMed ID: 37699361
[TBL] [Abstract][Full Text] [Related]
7. Expression and prognosis analysis of GINS subunits in human breast cancer.
Li H; Cao Y; Ma J; Luo L; Ma B
Medicine (Baltimore); 2021 Mar; 100(11):e24827. PubMed ID: 33725952
[TBL] [Abstract][Full Text] [Related]
8. SHCBP1 Is a Prognostic Biomarker Related to the Tumour Immune Microenvironment in Pan-Cancer.
Huang Y; You M; Wu Q; Zhu W; Guo F; Lin W
Ann Clin Lab Sci; 2022 Nov; 52(6):904-917. PubMed ID: 36564070
[TBL] [Abstract][Full Text] [Related]
9. High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients.
Zheng M; Zhou Y; Yang X; Tang J; Wei D; Zhang Y; Jiang JL; Chen ZN; Zhu P
Breast Cancer Res Treat; 2014 Nov; 148(2):423-36. PubMed ID: 25348432
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive analysis of the prognostic and immunological role of
Tan Y; Meng W; Jiang Z; Li N; Zhang T; Zhang J; Ma L; Guan Y
Transl Cancer Res; 2024 Feb; 13(2):1091-1113. PubMed ID: 38482441
[TBL] [Abstract][Full Text] [Related]
11. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and immunological role of Ras-related protein Rap1b in pan-cancer.
Cui G; Wang C; Lin Z; Feng X; Wei M; Miao Z; Sun Z; Wei F
Bioengineered; 2021 Dec; 12(1):4828-4840. PubMed ID: 34346294
[TBL] [Abstract][Full Text] [Related]
13. Systematic pan-cancer analyses of the potential function of the Golgi scaffold protein PAQR3.
Ling ZN; Hong LL; Wu J; Ling ZQ
Sci Rep; 2024 Feb; 14(1):3030. PubMed ID: 38321173
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive pan-cancer analysis on CBX3 as a prognostic and immunological biomarker.
Niu H; Chen P; Fan L; Sun B
BMC Med Genomics; 2022 Feb; 15(1):29. PubMed ID: 35172803
[TBL] [Abstract][Full Text] [Related]
15. A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis.
Chen R; Wu W; Chen SY; Liu ZZ; Wen ZP; Yu J; Zhang LB; Liu Z; Zhang J; Luo P; Zeng WJ; Cheng Q
Front Immunol; 2022; 13():831542. PubMed ID: 35979347
[TBL] [Abstract][Full Text] [Related]
16. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
17. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy.
Jia Y; Guo B; Zhang W; Wang F; Zhang Y; Zhang Q; Li E
Front Oncol; 2023; 13():1110207. PubMed ID: 37427102
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract][Full Text] [Related]
19. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
[TBL] [Abstract][Full Text] [Related]
20. RecQ mediated genome instability 2 (
Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]